Recent developments in immunotoxin therapy

Immunotoxin (IT) research has been ongoing for 15 years. During the past 2 years, work has focused on several areas: on improvements and developments in first- and second-generation ITs; the preparation of new immunotoxin constructs with anti-tumor activity; novel animal models for preclinical evalu...

Full description

Saved in:
Bibliographic Details
Published inCurrent opinion in immunology Vol. 6; no. 5; pp. 707 - 714
Main Authors Ghetie, Maria-Ana, Vitetta, Ellen S.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 1994
Subjects
Animals
Disease Models, Animal
Endothelium, Vascular - immunology
Humans
Immunotoxins - chemistry
Immunotoxins - immunology
Immunotoxins - therapeutic use
Mice
Mice, Nude
Mice, SCID
Neoplasms - immunology
Neoplasms - therapy
ALL
SCLC
TFR
CLL
SAP
BLR
IT
SCID
CR
GEL
DT
PLL
NHL
PEG
PE
ABMT
LAK
RIP
HUVEC
VLS
PAP
RTA
Online AccessGet full text

Cover

More Information
Summary:Immunotoxin (IT) research has been ongoing for 15 years. During the past 2 years, work has focused on several areas: on improvements and developments in first- and second-generation ITs; the preparation of new immunotoxin constructs with anti-tumor activity; novel animal models for preclinical evaluation of immunotoxins; and clinical trials, which are now entering Phase II or III in humans.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-3
content type line 23
ISSN:0952-7915
1879-0372
DOI:10.1016/0952-7915(94)90073-6